1. Home
  2. PEO vs PRTA Comparison

PEO vs PRTA Comparison

Compare PEO & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adams Natural Resources Fund Inc.

PEO

Adams Natural Resources Fund Inc.

HOLD

Current Price

$26.74

Market Cap

570.8M

Sector

Finance

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$10.50

Market Cap

539.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PEO
PRTA
Founded
1929
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
570.8M
539.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
PEO
PRTA
Price
$26.74
$10.50
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$19.00
AVG Volume (30 Days)
109.9K
507.8K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
5.93%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$814,000.00
Revenue This Year
N/A
$1,111.38
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.30
$4.32
52 Week High
$28.88
$11.69

Technical Indicators

Market Signals
Indicator
PEO
PRTA
Relative Strength Index (RSI) 50.65 65.42
Support Level $21.14 $9.69
Resistance Level $27.12 $10.90
Average True Range (ATR) 0.73 0.42
MACD -0.17 0.15
Stochastic Oscillator 37.87 92.39

Price Performance

Historical Comparison
PEO
PRTA

About PEO Adams Natural Resources Fund Inc.

Adams Natural Resources Fund Inc is a non-diversified U.S. equity fund that invests in liquid energy and other natural resources stocks. The Fund's investment objectives are preservation of capital, reasonable income, and opportunity for capital gain. A majority of its assets are invested in petroleum or natural resources industries or industries connected to them. It has broad flexibility to invest in stocks of varying capitalizations and predominantly invests in stocks found in the S&P 500 Energy and S&P 500 Materials sectors.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: